Immune cell-derived opioid peptides can activate opioid receptors on peripheral sensory nerves to inhibit inflammatory pain. The intrinsic mechanisms triggering this neuroimmune interaction are unknown. This study investigates the involvement of endogenous corticotropin-releasing factor (CRF) and interleukin-1p (IL-1). A 
Pain, evoked by local injury and inflammation, can be controlled effectively by peripherally acting opioids (1) . The local inflammatory response initiates the synthesis of opioid peptides within resident immune cells (2) . Upon release, these peptides produce analgesia mediated by opioid receptors on peripheral sensory nerves (3) . The endogenous impulse initiating this release is unknown. Corticotropin-releasing factor (CRF) and interleukin-l/3 (IL-1) are interesting candidates because both can liberate opioid peptides from the pituitary and from immune cells (3, 4) . Furthermore, they are detectable in the circulation during stress and they are also present in inflamed tissue (5, 6) . However, neither has been examined for its involvement in intrinsic pain inhibition.
In this study, we hypothesized that CRF or IL-1 might be the endogenous trigger for local opioid release and subsequent activation of peripheral opioid receptors in inflamed tissue. Previously, we have shown that a specific environmental stressful stimulus [cold water swim stress (CWS)] elicits potent peripheral opioid analgesia without involvement of central mechanisms (7) . Using this paradigm, we now examined whether local or systemic blockade of endogenous CRF or IL-1 interferes with this stress-induced antinociception. This block-
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 Algesiometry. Animals (n = 6-8 per group) were gently restrained under paper wadding and nociceptive thresholds were evaluated using a modified Randall-Selitto paw pressure test, as described (7) . At all times, the experimenter was blind to the condition employed. After baseline measurements, rats received an injection of either the test substance or vehicle. Five minutes later they were placed into a tub containing water at 1-2°C to swim for 1 min as described (7) . At the end of this swim stress, they were removed from the water, immediatly dried with paper wadding, and paw pressure threshold (PPT) was reevaluated repeatedly thereafter. Experiment 1. These experiments evaluated whether the receptor antagonists naloxone (18 jig), a-helical CRF (0.2-8 ng), IL-lra (0.001-1 jug), or vehicle (saline), given i.pl. or i.v., could influence antinociceptive effects induced by CWS. These drugs were given alone or 5 min before CWS, and nociceptive thresholds were evaluated 7, 12, and 22 min after injection. Dose-response curves were constructed at the time of peak effects of a-helical CRF and IL-lra. Experiment 2. Next we examined whether passive immunization with i.pl. anti-CRF (0.0001-10 jug) or anti-IL-lp (0.0001-10 ,tg) alters CWS-induced antinociception. In control experiments we used anti-CRF (10 tag) that was heat denatured at 95°C for 45 min, normal rabbit IgG (10 jLg), and antisera without CWS. In comparison, the effects of i.v. anti-CRF (0.2-400 jig) were examined. To mimic a possible systemic increase in circulating CRF, 10 (Fig. 1A) . However, it was antagonized by i.pl. naloxone (18 jig) (Fig. 1B) and by i.pl. (Fig. 1C) , but not by i.v. a-helical CRF (2 ng) (Fig. 1D) . The attenuation by i.pl. a-helical CRF was dose-dependent ( Fig.  2A) . IL-lra did not inhibit CWS-induced PPT elevations at concentrations between 0.001 and 1 jtg (Fig. 2A) . Given (Fig. 2A) . Experiment 2. CWS-induced PPT elevations were dosedependently reversed by i.pl. anti-CRF (Fig. 2B) . Neither heat-denatured anti-CRF (10 gig) nor normal rabbit IgG (10 jig) attenuated CWS effects (data not shown). Anti-CRF, given i.v., also inhibited CWS-induced effects (Fig. 2B ), but the required concentrations were 104-fold higher compared to the i.pl. route (i.pl. ED50 = 8.6 ng versus i.v. ED50 = 205 tLg). Intravenous injection of human/rat CRF (10 ng) at a 100-fold higher concentration than the average plasma CRF level (10 pg/ml) (12) did not produce any significant changes of PPT (data not shown). Anti-IL-l13 did not alter CWS-induced PPT elevations (Fig. 2B) . Administration of each antiserum alone had no effect (P > 0.05; Friedman test) (Fig. 2B) .
Experiment 3. Pretreatment of inflamed paws with CRF antisense ODN significantly reduced PPT elevations elicited by CWS (Fig. 3) Fig. 1A ), asterisks denote significant differences between baseline and post-CWS values (P < 0.05; Friedman and Wilcoxon tests) and the dagger denotes significant differences compared to the peak effect of the saline group (P < 0.05; Mann-Whitney U test). (Fig. 4A) . These cells occurred singly or in groups in the periphery of inflammatory foci within the plantar subcutaneous tissue. This immunostaining was abolished after preadsorption or omission of the primary antiserum (Fig. 4C ). In rats pretreated with i.pl. antisense ODN, CRF immunoreactivity was clearly diminished (Fig. 4B ) and the number of CRF-labeled cells was significantly reduced (by 48%) compared with saline-treated control animals ( (Table 1) . Gross morphology (edema and infiltration of inflammatory cells into the subcutaneous tissue) was similar among the four groups.
RIA. In vehicle pretreated animals the amount of CRF extracted from inflamed paws was 1475.2 ± 136.1 pg/g of wet tissue. CRF-antisense pretreatment significantly reduced the CRF content to 937.4 ± 84.9 pg/g of wet tissue (P < 0.01; Mann-Whitney U test).
DISCUSSION
The stress paradigm used in the present experiments produces pronounced antinociception in inflamed but not in noninflamed tissue. This effect is reversible by local administration of naloxone, indicating that peripheral opioid receptors are activated by endogenous opioids. Opioid receptors are expressed in dorsal root ganglia and present on peripheral sensory nerve terminals both in inflamed and in healthy tissue (13) (14) (15) , but opioid peptides, synthesized and released from immune cells, are found in inflamed tissue only (2, 13) . This apparently accounts for the differential CWS effects in inflamed and noninflamed paws. Since minimal changes in stress severity can activate different pain control systems (16, 17) , it is important to note that the present paradigm does not involve central pathways of stress-induced analgesia (7) . Rather, it is a tool to selectively investigate intrinsic antinociceptive mechanisms at the inflammatory site, which are based on a release of immune cell-derived opioids and their interaction with opioid receptors on sensory nerves (2, 13) .
What is the endogenous agent that induces the release of opioid peptides from immune cells? CRF and IL-13 are of particular interest because they stimulate such release in vitro and in vivo (3, 4 (12) . Taken together, these results strongly suggest that endogenous CRF originates from the inflammatory site and that plasma-derived CRF is not involved in producing this localized stress-induced effect.
Indeed, we found significant amounts of immunoreactive CRF in the inflamed tissue, which is consistent with previous studies in different models of inflammation (6, 19) . The concentration of local CRF was much higher than in plasma, supporting the notion that CRF might act in a paracrine manner (6) . If 
